$1.38
-0.04 (-2.82%)
Open$1.41
Previous Close$1.42
Day High$1.42
Day Low$1.37
52W High$1.96
52W Low$1.13
Volume—
Avg Volume91.8K
Market Cap68.17M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,965.2% upside
Current
$1.38
$1.38
Target
$28.50
$28.50
$17.57
$28.50 avg
$41.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 382.3K | 11.04M | 11.56M |
| Net Income | -11,262,103 | -536,425 | -578,623 |
| Profit Margin | -2,928.8% | -4.9% | -5.0% |
| EBITDA | -12,464,315 | -810,707 | -735,622 |
| Free Cash Flow | — | -370,627 | -351,629 |
| Rev Growth | — | +9.7% | -0.5% |
| Debt/Equity | — | 0.96 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |